Zynex Inc Stock Price, News & Analysis

Zynex (NASDAQ: ZYXI) announced engagement of Province, LLC to evaluate strategic alternatives, including potential capital raises, recapitalization and restructuring, and formed an independent Special Committee to oversee the process.

Paul Aronzon was appointed to the board and named Chair of the Special Committee; director Bret Wise will also serve. The committee will work with management, Province and counsel to assess options. The company cautioned no transaction has been identified and there is no assurance a transaction will occur.

Zynex (NASDAQ: ZYXI) will host its Q3 2025 earnings conference call on Tuesday, November 18, 2025 at 9:00 AM ET (7:00 AM MT) to discuss results for the quarter ended September 30, 2025. A press release with financial results will be issued prior to the call. Management will host the call and provide a live webcast.

Dial-in numbers are U.S. & Canada: 800-836-8184 and International: 646-357-8785. A webcast link will be available at https://zynexmed.investorroom.com/. Callers are asked to dial in 5–10 minutes early.

Zynex (NASDAQ: ZYXI) announced on October 14, 2025 that Bret Wise has been appointed to its Board of Directors and will serve as Chair of the Audit Committee. Mr. Wise is a retired senior medical‑device executive with multi‑role experience at Dentsply (President, COO, CFO; CEO 2007–2016; Executive Chair 2016–2017), prior CFO roles at two public companies, and earlier service as an audit partner at KPMG. He has served on public boards including IMS Health and Pall and currently sits on private and clinical advisory boards. Company leadership said the appointment reinforces a renewed focus on financial oversight, integrity, and compliance.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices, has announced significant leadership changes with the arrival of Steven Dyson as CEO and several key executive appointments effective August 18, 2025.

The new leadership team includes Vikram Bajaj as CFO, bringing 20 years of med-tech sector experience, John T. Bibb as Chief Legal Officer with extensive legal and compliance background, Ajay Gopal as EVP of Sales with proven commercial leadership experience, and Agnes Powell as VP of Billing with 20 years in revenue cycle operations.

The executive leadership team will be completed by existing members Anna Lucsok (COO) and Donald Gregg (President of Zynex Monitoring Solutions). Chairman Thomas Sandgaard expressed confidence in the new team's ability to lead Zynex to new levels of success.

Zynex (NASDAQ: ZYXI) reported challenging Q2 2025 financial results, with net revenue declining to $22.3 million from $49.9 million year-over-year. The company posted a net loss of ($20.0 million), or ($0.66) per share, compared to net income of $1.2 million in Q2 2024.

Two significant developments marked the quarter: the appointment of Steven Dyson as new CEO, bringing 25 years of medical technology experience, and the FDA submission of their NiCO laser pulse oximeter. The company implemented efficiency improvements targeting $40 million in annualized savings, primarily effective in Q3 and Q4. Due to leadership changes, Zynex has temporarily suspended revenue and profitability guidance.

Cash and cash equivalents stood at $17.5 million, with quarterly cash collections of $26.1 million. The company's gross profit margin decreased to 68% from 80% year-over-year, affected by the Tricare payment suspension and ongoing operational restructuring.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has scheduled its Q2 2025 earnings conference call for July 31, 2025, at 4:15 PM ET.

The company will release its financial results for the quarter ended June 30, 2025, before the call. Management will host the call followed by a Q&A session. Participants can join via phone using the U.S. & Canada dial-in (800-836-8184) or international number (646-357-8785), or through the webcast available on the company's investor relations website.

Zynex (NASDAQ: ZYXI), a medical technology company focused on non-invasive medical devices, announced that Tricare, their largest insurance customer, will continue its temporary payment suspension. Despite appealing the suspension and meeting with Tricare officials in April to present data supporting the lifting of the suspension, Tricare has decided to maintain the temporary hold while conducting further review.

The company's CEO, Thomas Sandgaard, confirmed that the suspension will remain in effect until Tricare reaches its final decision. This development represents a significant challenge for Zynex, as Tricare is identified as their largest insurance customer.

Zynex (NASDAQ: ZYXI), a medical technology company focused on noninvasive medical devices for pain management, rehabilitation, and patient monitoring, has announced the appointment of Steven Dyson as its new Chief Executive Officer, effective August 18, 2025.

Dyson brings over 25 years of experience in the medical technology sector, primarily through his leadership at Apax, a global private equity firm. His extensive background includes significant board and transaction experience with various healthcare and medtech companies worldwide, including KCI, Rodenstock, Healthium Medtech, Unilabs, and Neuraxpharm.

Thomas Sandgaard, Zynex's Founder and current Chairman, will step back from day-to-day operations but remain actively involved as Chairman and Chair of the Board's Technology Committee. Dyson will operate from the company's headquarters in Englewood, Colorado, while maintaining a residence in London, England.

Zynex (NASDAQ: ZYXI) has secured UK patent 2617515 for a novel multiparameter, noninvasive sepsis monitoring device. The technology aims to address a critical global health crisis, as sepsis affects 1.7 million people annually in the US alone and causes 11 million deaths globally, with one-third of hospital deaths being sepsis-related.

The device will continuously monitor physiological signals to provide early alerts about patient sepsis status, leveraging Zynex's cardiac monitoring expertise. Early detection is crucial for patient recovery, as highlighted by the Surviving Sepsis Campaign. The technology could significantly impact treatment outcomes, particularly considering that over 50% of sepsis cases are hospital-acquired and current detection methods face timing challenges.